• OncoMed Pharmaceuticals Inc., of Redwood City, Calif., said patient dosing has begun in a Phase I trial of OMP-54F28, a fusion protein based on a truncated form of the Frizzled8 receptor, in advanced solid tumor cancers. The open-label, dose-escalation study will assess safety, immunogenicity, pharmacokinetics, biomarkers and initial signals of efficacy. The drug is part of the firm's collaboration with Leverkusen, Germany-based Bayer AG.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter